In 2002, the first III generation antipsychotic drug was registered—aripiprazole. Its partial dopaminergic agonism underlies its unique mechanism of action and the potentially beneficial influence on the positive, negative, or cognitive symptoms. Due to its relatively high intrinsic activity, the drug could often cause agitation, anxiety, or akathisia. For this reason, efforts were made to develop a drug which would retain the positive favorable actions of aripiprazole but present a more advantageous clinical profile. This turned out to be brexpiprazole, which was registered in 2015. Its pharmacodynamic and pharmacokinetic profile (similarly to the other most recent antipsychotics, i.e., lurasidone or cariprazine) shows promise of increasing the effectiveness of schizophrenia treatment in the dimensions in which the previous antipsychotics were not sufficiently effective, including negative, depressive, or cognitive symptoms. Like other new antipsychotics, it can also be useful in the treatment of mood disorders, for instance drug-resistant depression. Previous reviews focused on the use of brexpiprazole in specific diagnostic groups. The aim of this article is to provide the readers with an overview of data on the mechanism of action, clinical effectiveness in all studied diagnostic groups, as well as potential drug–food interactions, and the safety of brexpiprazole.
No abstract
Purpose: An assessment of the subjective experience of admission and first days of hospitalization at a psychiatric hospital and an analysis of its associations with socio-demographic and clinical factors. Methods: Analyses comprised data on 297 subjects. Diagnoses comprised the whole spectrum of F0-F9 according to ICD-10, the most numerous being F2 (39%), F1 (17%), F3 (16%) and F0 (11%). 30% of the subjects were hospitalised for the first time and 18% were admitted without consent. They were asked to evaluate the situation of being admitted and the first days of their hospitalization 4 to 10 days after the admission. The FEA-P questionnaire was used, with seven dimensions: attitude towards staff, explanation of treatment plan, housing conditions, critical remarks to staff, perception of other patients, perception of ward rules and ward atmosphere.
concerning newly approved antipsychotic medication. We summarised information about pharmacodynamic effects, pharmacokinetics, clinical efficacy and tolerance of described medications. Conclusions. Newly approved antipsychotic medication seem to give hope of improvement of treatment efficacy, especially with regards to negative, cognitive and depress ive symptoms of schizophrenia. They also seem to be bet ter tolerated than previously available antipsychotics. StreSzczenieCel. Celem pracy było przedstawienie informacji do tyczących mechanizmów działania, farmakokinetyki, skuteczności klinicznej oraz tolerancji nowych leków przeciwpsychotycznych -lurasidonu, brekspipra zolu, kariprazyny, lumateperonu i pimawanseryny -a także porównanie ich z dotychczas dostępnymi preparatami. Przegląd piśmiennictwa. Dokonano przeglądu badań klinicznych, przedklinicznych, przeglądu literatury oraz metaanaliz dotyczących opisanych leków. Podsumowano informacje dotyczące efektów farmakodynamicznych, farmakokinetyki, skuteczności klinicznej oraz tolerancji opisanych leków. Wnioski. Opisane w artykule leki wydają się dawać nadzieję na poprawę skuteczności leczenia schizofre nii, szczególnie w zakresie jej objawów negatywnych, poznawczych i depresyjnych. Wydają się również lepiej tolerowane niż dotychczas stosowane preparaty.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.